United Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 8.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,188 shares of the biotechnology company's stock after selling 11,423 shares during the period. Retirement Systems of Alabama owned about 0.26% of United Therapeutics worth $36,434,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Signaturefd LLC grew its holdings in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after buying an additional 30 shares in the last quarter. Parallel Advisors LLC raised its stake in United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after purchasing an additional 30 shares in the last quarter. Anchor Investment Management LLC raised its stake in United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 30 shares in the last quarter. Great Lakes Advisors LLC lifted its position in United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after purchasing an additional 31 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its position in United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after purchasing an additional 33 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. JPMorgan Chase & Co. decreased their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Finally, Cantor Fitzgerald began coverage on United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $393.08.

United Therapeutics Stock Down 0.3%

Shares of UTHR traded down $0.97 during midday trading on Friday, reaching $290.75. The company had a trading volume of 1,455,383 shares, compared to its average volume of 450,139. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82. The firm has a 50 day simple moving average of $300.99 and a 200-day simple moving average of $327.67. The stock has a market cap of $13.12 billion, a PE ratio of 11.60, a price-to-earnings-growth ratio of 6.37 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company's revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the business posted $6.17 EPS. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the transaction, the chief financial officer now owns 8,118 shares in the company, valued at $2,641,353.66. The trade was a 59.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This trade represents a 22.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock valued at $23,907,950 in the last three months. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.